Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

bcl-2 protein in non-small-cell lung carcinoma

Article Abstract:

The five-year survival rate may be higher for non-small-cell lung cancer patients with abnormal production of bcl-2 protein. Bcl-2 protein is the product of the bcl-2 proto-oncogene. The bcl-2 proto-oncogene may be involved in the regulation of cell death rather than cell division. Among 122 patients who had surgery for non-small-cell lung cancer, 80 had squamous-cell carcinoma and 42 had adenocarcinoma. Abnormal production of bcl-2 protein was found in 25% of the patients with squamous-cell carcinoma and 12% of those with adenocarcinoma. Patients with bcl-2 protein were likely to survive five years after diagnosis than those without. Patients over 60 years old with bcl-2 protein had the highest chance of survival.

Author: Mason, David Y., Turley, Helen, Pezzella, Francesco, Suzu, Isinzu, Tungekar, Mohammed Fahim, Dunnill, Michael S., Pierce, Chris B., Harris, Adrian, Gatter, Kevin c.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1993
Physiological aspects, Development and progression, Oncogenes, Lung cancer, Non-small cell, Non-small cell lung cancer

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Sorafenib in advanced clear-cell renal-cell carcinoma

Article Abstract:

A phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis in patients with advanced clear-cell renal-cell carcinoma was conducted. Results revealed that oral sorafenib therapy prolonged progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom first-line therapy had failed.

Author: Escudier, Bernard; Eisen, Tim; Stadler, Walter M.; Szczylik, Cezary; Oudard, Stephane; Siebels, Michael
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2007
Drug therapy, Dosage and administration, Carcinoma, Renal cell, Renal cell carcinoma, Drug overview, Sorafenib

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Similar abstracts:
  • Abstracts: High-dose methylprednisolone in the treatment of spinal cord injuries. Treatment strategies in shock: use of oxygen transport measurements
  • Abstracts: New options for diagnosis and treatment of ectopic pregnancy. Diagnosis of Duchenne and Becker muscular dystrophies by polymerase chain reaction: a multicenter study
  • Abstracts: Population-based mortality assessment: Baidoa and Afgoi, Somalia, 1992. Reduced mortality risk in alcoholics who achieve long-term abstinence
  • Abstracts: AMA's violence report card: nation gets poor grades again. America the violent: this nation's rotten report card on how it deals with violence is a call to action
  • Abstracts: Directly observed preventive therapy: turning the tide against tuberculosis. Health officials throughout country see jump in TB cases
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.